Ovarian Cancer
6 competing products in clinical development for Ovarian Cancer.
Pipeline by Phase
Phase 11
Phase 1/21
Phase 24
All Products (6)
| Product | Company | Stage | Status | Hype |
|---|---|---|---|---|
| arzoxifene hydrochloride | Eli Lilly | Phase 2 | Completed | 52 |
| Prexasertib | Eli Lilly | Phase 2 | Completed | 52 |
| Gemcitabine + Oxaliplatin + Bevacizumab | Eli Lilly | Phase 2 | Terminated | 52 |
| Durvalumab + BA3011 + BA3021 + ENB003 + Toripalimab | BioAtla | Phase 2 | Recruiting | 44 |
| Azenosertib + Niraparib | Zentalis Pharmaceuticals | Phase 1/2 | Completed | 33 |
| pemetrexed + topotecan | Eli Lilly | Phase 1 | Completed | 33 |